Aurobindo Pharma Limited (NSE:AUROPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 656.25B |
| Revenue (ttm) | 317.24B |
| Net Income (ttm) | 34.86B |
| Shares Out | 580.80M |
| EPS (ttm) | 59.81 |
| PE Ratio | 18.89 |
| Forward PE | 16.37 |
| Dividend | 3.00 (0.26%) |
| Ex-Dividend Date | n/a |
| Volume | 1,058,782 |
| Average Volume | 1,259,685 |
| Open | 1,135.00 |
| Previous Close | 1,129.90 |
| Day's Range | 1,115.20 - 1,139.00 |
| 52-Week Range | 1,010.00 - 1,592.00 |
| Beta | 0.20 |
| RSI | 43.83 |
| Earnings Date | Aug 14, 2025 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi... [Read more]
Financial Performance
In 2024, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.
Financial StatementsNews
Aurobindo Pharma shares slip nearly 3% after Macquarie downgrades stock, cuts target price to Rs 1,010
Aurobindo Pharma shares were under pressure in early trade, falling close to 3% after brokerage firm Macquarie issued a double downgrade on the stock. The firm revised its rating to ‘underperform’ fro...
Top stocks in focus on July 3: Nestle India, Aurobindo Pharma, Hindustan Zinc, V2 Retail, CSB Bank and more
Indian benchmark indices ended lower on Wednesday, July 2. The NSE Nifty 50 declined by 88 points or 0.35% to settle at 25,453.40, while the BSE Sensex dropped 287.60 points or 0.34%, closing at 83,40...
Aurobindo Pharma’s subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys’
Aurobindo Pharma’s wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzu...
Aurobindo Pharma’s CuraTeQ secures UK’s MHRA approval for Dyrupeg
CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for...
Nuvama bullish on Aurobindo Pharma, sees 15% profit CAGR through FY27
Nuvama Institutional Equities has reiterated a ‘Buy’ call on Aurobindo Pharma, with a target price of ₹1,460, as it sees the stock poised for a strong recovery led by new product launches, capacity ex...
Pharma stocks in focus as Trump announces tariffs on sector ‘soon’
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenu...
Aurobindo Pharma's US arm incorporates new subsidiary called Cresedemo Pharma
HYDERABAD: Aurobindo Pharma on Monday informed the bourses that its wholly-owned US subsidiary, Aurobindo Pharma USA Inc, has incorporated a wholly-ow.
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
In May, the U.S. District Court for the District of Delaware ruled in favor of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) regarding its ‘721 formulation patent for Nuplazid (pimavanserin), Acadia’s d...
Top stocks to buy today: Stock recommendations for May 30, 2025
Stock market recommendations: Bajaj Broking Research suggests a resilient Indian equity market, projecting Nifty consolidation between 24,400-25,200 with a bullish outlook supported by rate cut expect...
Aurobindo Pharma shares fall over 2% after Citi maintains ‘Sell’ rating, cuts target price to Rs 1,100
Aurobindo Pharma shares fell over 2% after Citi maintained a ‘Sell’ rating and lowered its target price to ₹1,100. Citi expressed concerns about flattening growth in the US market and rising margin pr...
Motilal Oswal retains ‘Buy’ on Aurobindo Pharma, sets target at Rs 1,370 on strong EU presence, growth visibility
Motilal Oswal has maintained a Buy rating on Aurobindo Pharma with a target price of ₹1,370, citing strong Q4 performance, recovery in production, and growth traction in European markets. The brokerag...
Nuvama cuts Aurobindo Pharma target to Rs 1,485 but retains ‘Buy’ on healthy EBITDA margin
Nuvama Institutional Equities has retained its Buy rating on Aurobindo Pharma (ARBP) but revised its target price down to ₹1,485 from ₹1,677, citing a mixed Q4 performance and a cautious FY26 outlook....
Stocks to watch today on May 28: LIC, Aurobindo Pharma, Info Edge among top brokerage picks
Brokerage firms have released fresh research notes on key Indian stocks post Q4FY25 earnings. Life Insurance Corporation of India (LIC), Aurobindo Pharma, and Info Edge are among the most discussed, w...
CLSA trims FY26-27 estimates for Aurobindo Pharma after Pen-G plant disruption
CLSA has reiterated its ‘Outperform’ rating on Aurobindo Pharma, with a target price of ₹1,400, following its highest-ever revenue and EBITDA performance in Q4FY25. Revenue rose to ₹8,382 crore, while...
HSBC advises to Buy Aurobindo Pharma, says long-term outlook intact despite EBITDA miss
HSBC has maintained a ‘Buy’ rating on Aurobindo Pharma, setting a target price of ₹1,415. The company posted an in-line revenue performance in Q4FY25 but missed on EBITDA due to higher-than-expected o...
Goldman Sachs retains ‘Buy’ on Aurobindo Pharma, sees value in stock despite gRevlimid headwinds
Goldman Sachs has reaffirmed its ‘Buy’ call on Aurobindo Pharma with a target price of ₹1,275, viewing the Q4FY25 results as decent despite upcoming challenges. Revenue came in at ₹8,382 crore, up 10....
Citi maintains ‘Sell’ on Aurobindo Pharma after Q4 results, trims earnings estimates on margin risks post gRevlimid
Citi has maintained a ‘Sell’ rating on Aurobindo Pharma and cut its target price to ₹1,100, flagging concerns around flattening growth in the US market and rising margin risks in the coming quarters. ...
Top stocks to watch today, May 27: Lupin, Aurobindo Pharma, NHPC, KEC International, Shilpa Medicare and more
Indian benchmark indices ended higher on Monday, May 26, 2025, supported by positive domestic and global cues. The BSE Sensex gained 455.37 points (0.56%) to close at 82,176.45, while the NSE Nifty50 ...
Q4 earning results today: Aurobindo, Gillette, KEC, FirstCry among key earnings to watch on 26 May
More than 50 listed companies are set to declare their Q4FY25 earnings on 26 May 2025, keeping the focus squarely on stock-specific action. Key companies scheduled to report include Aurobindo Pharma, ...
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) announced a favorable court ruling on Friday . The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia’s ‘7...
PNB, L&T & more: Top stocks on brokers' radar for May 12
Nomura remains positive on CG Power despite margin concerns in its railway business, while Citigroup is bearish on PNB due to profitability and asset quality issues. Citi is optimistic about HPCL, rev...
Top stocks to buy today: Stock market recommendations for May 6, 2025
Stock market recommendations: Mirae Asset Sharekhan suggests buying Aurobindo Pharma, anticipating a breakout from a flag pattern with a target of Rs 1356, and IRCTC, expecting an upward trend to Rs 8...
Aurobindo Pharma shares drop 3% after company reports fire incident at Kakinada plant
Aurobindo Pharma’s stock witnessed a 3% dip following a fire incident at its Penicillin-G manufacturing facility in Kakinada SEZ, Andhra Pradesh. The fire, which occurred near the coal crusher area, c...
Aurobindo Pharma reports fire incident at Andhra Pradesh facility, operations temporarily paused
Aurobindo Pharma Limited on Sunday informed exchanges about a fire incident at one of its manufacturing facilities operated by its wholly owned stepdown subsidiary, Lyfius Pharma Private Limited, loca...
Aurobindo Pharma subsidiary receives positive opinion for biosimilar Dazublys from EMA
CuraTeQ Biologics s.r.o., a subsidiary of Aurobindo Pharma Limited, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a po...